Federation Francophone de Cancerologie Digestive
Federation Francophone de Cancerologie Digestive
Explore linked clinical trials.19 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2026-06-15 | NCT02945033 | |
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. | Borderline Resectable Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-06-11 | NCT07616362 | |
| Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not applicable | 2026-05-26 | NCT07124858 | |
| Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2026-05-20 | NCT07205731 | |
| A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC) | Pancreas Adenocarcinoma (MSI-H); Pancreatic Cancer Resectable | Not yet recruiting | Not applicable | 2026-05-18 | NCT07592819 | |
| Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma | signet ring cell gastric adenocarcinoma | Recruiting | Not applicable | 2026-05-14 | NCT01717924 | |
| Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma | neoplasm | Recruiting | Phase 3 | 2026-02-05 | NCT07270991 | |
| Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-01-13 | NCT07337447 | |
| Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma | Cholangiocarcinoma Non-resectable; Non-metastatic | Recruiting | Phase 2 | 2026-01-05 | NCT03364530 | |
| Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM) | Colorectal Cancer Metastatic; Microsatellite Instability-High Colorectal Cancer | Recruiting | Not stated | 2025-10-06 | NCT06353854 | |
| Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 2 | 2025-09-08 | NCT07150403 | |
| Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA | Anal Cancer, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anus disorder, anus neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Recruiting | Phase 3 | 2025-09-02 | NCT06207981 | |
| Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2025-09-02 | NCT05706779 | |
| National Cohort of Colorectal Cancers With Microsatellite Instability | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not stated | 2025-09-02 | NCT05511688 | |
| PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Not yet recruiting | Phase 2 | 2025-08-17 | NCT07128290 | |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 2 | 2025-08-15 | NCT07124884 | |
| A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, cholangiocarcinoma, combined hepatocellular carcinoma and cholangiocarcinoma, epithelial neoplasm, fibrolamellar hepatocellular carcinoma, hepatoblastoma, liver disorder, liver neuroendocrine carcinoma, mixed neoplasm, neoplasm | Recruiting | Not stated | 2025-08-05 | NCT06541652 | |
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2025-07-09 | NCT02885753 | |
| Prospective Cohort of Patients With Hepatocellular Carcinoma in France | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver cancer, liver disorder, neoplasm | Recruiting | Not stated | 2025-06-10 | NCT04348838 |